{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:21:47Z","timestamp":1793931707384,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI115469"],"award-info":[{"award-number":["R01AI115469"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_219361"],"award-info":[{"award-number":["310030_219361"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jaci.2025.05.028","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:14:02Z","timestamp":1760346842000},"page":"1290-1302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo"],"prefix":"10.1016","volume":"156","author":[{"given":"Daniel","family":"Brigger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Guntern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke F.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"van Brummelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Jardetzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8746-3339","authenticated-orcid":false,"given":"Alexander","family":"Eggel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.05.028_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature07204","article-title":"The development of allergic inflammation","volume":"454","author":"Galli","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2025.05.028_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","article-title":"IgE in allergy and asthma today","volume":"8","author":"Gould","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-immunol-061020-053712","article-title":"IgE, IgE receptors and anti-IgE biologics: protein structures and mechanisms of action","volume":"41","author":"McDonnell","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib4","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/all.14724","article-title":"The role of CD23 in the regulation of allergic responses","volume":"76","author":"Engeroff","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.05.028_bib5","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.1073\/pnas.1207278109","article-title":"Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor Fc RI","volume":"109","author":"Dhaliwal","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2025.05.028_bib6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/mi.2015.16","article-title":"Inhibition of CD23-mediated IgE transcytosis suppresses the initiation and development of allergic airway inflammation","volume":"8","author":"Palaniyandi","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.20050811","article-title":"The structure of human CD23 and its interactions with IgE and CD21","volume":"202","author":"Hibbert","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2025.05.028_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovi\u0107","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.05.028_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.05.028_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.05.028_bib11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.05.028_bib12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib14","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.05.028_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.05.028_bib16","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.4049\/jimmunol.162.9.5624","article-title":"Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo","volume":"162","author":"Saini","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib17","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/72601","article-title":"The pharmacological basis of anti-IgE therapy","volume":"18","author":"Chang","year":"2000","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaci.2025.05.028_bib19","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jaci.2014.02.005","article-title":"Accelerated dissociation of IgE-Fc\u03b5RI complexes by disruptive inhibitors actively desensitizes allergic effector cells","volume":"133","author":"Eggel","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11610","article-title":"Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange","volume":"7","author":"Pennington","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.05.028_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nature11546","article-title":"Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor","volume":"491","author":"Kim","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2025.05.028_bib22","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.183.4.1303","article-title":"Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody","volume":"183","author":"Coyle","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2025.05.028_bib23","first-page":"231","article-title":"Demonstration of the therapeutic potential of non-anaphylactogenic anti-IgE antibodies in murine models of skin reaction, lung function and inflammation","volume":"113","author":"Heusser","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00751-2020","article-title":"Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3+Tregs","volume":"57","author":"L\u00f3pez-Abente","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2025.05.028_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrd1334","article-title":"Omalizumab","volume":"3","author":"Ames","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2025.05.028_bib26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaip.2015.12.002","article-title":"Monitoring allergic patients on omalizumab with free and total serum IgE measurements","volume":"4","author":"Hamilton","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.05.028_bib27","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4161\/mabs.22216","article-title":"Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies","volume":"4","author":"Mortensen","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.jaci.2025.05.028_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1208\/s12248-008-9045-4","article-title":"Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody","volume":"10","author":"Putnam","year":"2008","journal-title":"AAPS J"},{"key":"10.1016\/j.jaci.2025.05.028_bib29","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1038\/s41467-021-27397-z","article-title":"Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex","volume":"12","author":"Pennington","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.05.028_bib30","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2125.2006.02803.x","article-title":"A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab","volume":"63","author":"Hayashi","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2025.05.028_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-2776(06)93002-8","article-title":"Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases","volume":"93","author":"Chang","year":"2007","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2009.03401.x","article-title":"Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma","volume":"68","author":"Lowe","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2025.05.028_bib33","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jaci.2021.08.006","article-title":"A novel functional mast cell assay for the detection of allergies","volume":"149","author":"Zb\u00e4ren","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib34","first-page":"579","volume":"Volume 1","author":"Bachmeier-Zb\u00e4ren","year":"2024"},{"key":"10.1016\/j.jaci.2025.05.028_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0165-2478(95)00014-V","article-title":"IgE-producing hybridomas established after B-cell culture in the CD40 system","volume":"46","author":"Z\u00fcrcher","year":"1995","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jaci.2025.05.028_bib36","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4049\/jimmunol.157.4.1645","article-title":"Anaphylaxis mediated through a humanized high affinity IgE receptor","volume":"157","author":"Dombrowicz","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib37","doi-asserted-by":"crossref","first-page":"10474","DOI":"10.1021\/bi00033a020","article-title":"Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE","volume":"34","author":"Liu","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.jaci.2025.05.028_bib38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1185\/030079903125002171","article-title":"Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma","volume":"19","author":"Hochhaus","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaci.2025.05.028_bib39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1398-9995.1981.tb01871.x","article-title":"IgE concentrations measured by PRIST\u00ae in serum of healthy adults and in patients with respiratory allergy","volume":"36","author":"Zetterst\u00f6m","year":"1981","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.05.028_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jaci.2006.01.012","article-title":"Accuracy of US Food and Drug Administration\u2013cleared IgE antibody assays in the presence of anti-IgE (omalizumab)","volume":"117","author":"Hamilton","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib42","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaci.2011.11.029","article-title":"Reduction of total IgE by targeted coengagement of IgE B-cell receptor and Fc\u03b3RIIb with Fc-engineered antibody","volume":"129","author":"Chu","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib43","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1016\/j.molimm.2008.06.027","article-title":"Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and Fc\u03b3RIIb with Fc-engineered antibodies","volume":"45","author":"Chu","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.coi.2018.05.015","article-title":"Targeting IgE in allergic disease","volume":"54","author":"Gasser","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib45","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaci.2016.02.027","article-title":"Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses","volume":"138","author":"Gauvreau","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1255","article-title":"Ligelizumab treatment for severe asthma: learnings from the clinical development programme","volume":"10","author":"Trischler","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.jaci.2025.05.028_bib47","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood-2008-05-154773","article-title":"Basophil effector function and homeostasis during helminth infection","volume":"113","author":"Ohnmacht","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.05.028_bib48","first-page":"225","article-title":"Production and life span of cutaneous mast cells in young rats","volume":"128","author":"Kiernan","year":"1979","journal-title":"J Anat"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925006232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925006232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:28:28Z","timestamp":1778880508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674925006232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0091674925006232"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.05.028","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}